We used this pharmacological tool, flow cytometry, confocal immunofluorescence, single cell DNA electrophoresis, mRNA-sequencing, mass spectrometry-based proteomics, and quantitative measurement of protein acetylation sites to evaluate the relevance of HDAC10 in human acute B and T lymphocytic leukemia (ALL), acute myeloid leukemia (AML) cells, and lymphoma cells. Here, HDAC10 is linked to lymphoma.